Literature DB >> 19401608

Complications of HIV disease and antiretroviral therapy.

Judith S Currier1, Diane V Havlir.   

Abstract

Continued progress in the diagnosis, management, and prevention of complications of HIV disease and antiretroviral therapy were reported at the 16th Conference on Retroviruses and Opportunistic Infections. This year's conference brought new data on the optimal management of antiretroviral therapy in the presence of different opportunistic infections and included a number of important studies on pathogenesis and epidemiology of long-term complications. Major areas in which new information was presented are highlighted in this article.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19401608

Source DB:  PubMed          Journal:  Top HIV Med        ISSN: 1542-8826


  8 in total

1.  A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study.

Authors:  Ighovwerha Ofotokun; Anandi N Sheth; Sara E Sanford; Kirk A Easley; Neeta Shenvi; Kelly White; Molly E Eaton; Carlos Del Rio; Jeffrey L Lennox
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-20       Impact factor: 2.205

2.  Gonadotropin and sex steroid levels in HIV-infected premenopausal women and their association with subclinical atherosclerosis in HIV-infected and -uninfected women in the women's interagency HIV study (WIHS).

Authors:  Roksana Karim; Wendy J Mack; Naoko Kono; Phyllis C Tien; Kathryn Anastos; Jason Lazar; Mary Young; Mardge Cohen; Elizabeth Golub; Ruth M Greenblatt; Robert C Kaplan; Howard N Hodis
Journal:  J Clin Endocrinol Metab       Date:  2013-02-15       Impact factor: 5.958

3.  Patient and provider-reported symptoms in the post-cART era.

Authors:  E J Edelman; K Gordon; A C Justice
Journal:  AIDS Behav       Date:  2011-05

4.  Synbiotic therapy decreases microbial translocation and inflammation and improves immunological status in HIV-infected patients: a double-blind randomized controlled pilot trial.

Authors:  Luz A González-Hernández; Luis F Jave-Suarez; Mary Fafutis-Morris; Karina E Montes-Salcedo; Luis G Valle-Gutierrez; Ariel E Campos-Loza; Luis Fermin Enciso-Gómez; Jaime F Andrade-Villanueva
Journal:  Nutr J       Date:  2012-10-29       Impact factor: 3.271

5.  Impact of immunodepression and moderate alcohol consumption on coronary and other arterial disease events in an 11-year cohort of HIV-infected patients on antiretroviral therapy.

Authors:  Maria Patrizia Carrieri; Camelia Protopopescu; Vincent Le Moing; Philippe Reboud; François Raffi; Sophie Mahy; Perrine Roux; Lise Cuzin; Bruno Spire; Catherine Leport
Journal:  BMJ Open       Date:  2012-11-23       Impact factor: 2.692

6.  Perturbations of circulating levels of RANKL-osteoprotegerin axis in relation to lipids and progression of atherosclerosis in HIV-infected and -uninfected adults: ACTG NWCS 332/A5078 Study.

Authors:  Theodoros Kelesidis; Michelle A Kendall; Otto O Yang; Howard Hodis; Judith S Currier
Journal:  AIDS Res Hum Retroviruses       Date:  2013-02-25       Impact factor: 1.723

Review 7.  Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection.

Authors:  Theodoros Kelesidis; Judith S Currier; Otto O Yang; Todd T Brown
Journal:  AIDS Rev       Date:  2014 Jul-Sep       Impact factor: 2.381

8.  Practicalities and challenges in re-orienting the health system in Zambia for treating chronic conditions.

Authors:  Carolien J Aantjes; Tim K C Quinlan; Joske F G Bunders
Journal:  BMC Health Serv Res       Date:  2014-07-08       Impact factor: 2.655

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.